Mitogen-activated protein kinase pathway protein-protein interfaces (MAPK PPIs)

The Mitogen-Activated Protein Kinase (MAPK) pathway protein-protein interfaces (PPIs) are essential structural and functional junctions that facilitate the relay of signals from the cell surface to the nucleus. These interfaces include specific docking sites, such as the D-site and FXF motif, and interactions with scaffold proteins like KSR1 that ensure the sequential activation and specificity of the RAS-RAF-MEK-ERK cascade (Source: PubMed, PMID: 30213718). Dysregulation of these interfaces is a hallmark of various malignancies, where mutations in upstream proteins like RAS or RAF lead to aberrant, constitutive signaling and uncontrolled tumorigenesis (Source: Nature Reviews Drug Discovery, doi:10.1038/nrd.2016.227). Targeting PPIs within the MAPK pathway is an emerging therapeutic strategy aimed at improving selectivity and reducing the systemic side effects associated with traditional ATP-competitive kinase inhibitors. By disrupting specific interactions or utilizing allosteric sites, these therapeutic agents can selectively inhibit pathological signaling while potentially overcoming common resistance mechanisms (Source: UniProt, P27361, P28482).

Other names

MAPK signaling interfacesMAPK docking sitesMAPK-scaffold interactionsMAPK protein complexesRAS-RAF-MEK-ERK interfaces

Disruption of physical interactions between kinases, substrates, or scaffold proteins to prevent signal propagation and allosteric modulation of kinase activity.